Clinical utility of dabigatran in United Arab Emirates

References

1. ↵
   1. Centers for Disease Control and Prevention (CDC)

   Atrial Fibrillation. CDC, Available from:http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/docs/fs_atrial_fibrillation.pdf. Accessed 2014 December.
2. ↵
   1. Lip GY,
   2. Brechin CM,
   3. Lane DA

   (2012) The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 142:1489–1498.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Pan X,
   2. Simon TA,
   3. Hamilton M,
   4. Kuznik A

   (2015) Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the United States. J Thromb Thrombolysis 39:508–515.

   OpenUrlCrossRefPubMed
4. ↵
   1. McBride D,
   2. Mattenklotz AM,
   3. Willich SN,
   4. Brüggenjürgen B

   (2009) The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. Value Health 12:293–301.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery,
   2. Camm AJ,
   3. Kirchhof P,
   4. Lip GY,
   5. Schotten U,
   6. et al.

   (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–2429.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Yap YG,
   2. Camm J

   (2014) Epidemiology of Atrial fibrillation. In Essentials of Atrial fibrillation (Springer Healthcare, London (UK)), pp 1–5.
7. ↵
   1. Wolowacz SE,
   2. Samuel M,
   3. Brennan VK,
   4. Jasso-Mosqueda JG,
   5. Van Gelder IC

   (2011) The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace 13:1375–1385.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Gladstone DJ,
   2. Bui E,
   3. Fang J,
   4. Laupacis A,
   5. Lindsay MP,
   6. Tu JV,
   7. et al.

   (2009) Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 40:235–240.

   OpenUrlAbstract/FREE Full Text
9. ↵
   1. Banerjee A,
   2. Fauchier L,
   3. Vourc’h P,
   4. Andres CR,
   5. Taillandier S,
   6. Halimi JM,
   7. et al.

   (2013) Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol 61:2079–2087.

   OpenUrlFREE Full Text
10. ↵
    1. Coppens M,
    2. Eikelboom JW,
    3. Hart RG,
    4. Yusuf S,
    5. Lip GY,
    6. Dorian P,
    7. et al.

    (2013) The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J 34:170–176.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Pisters R,
    2. Lane DA,
    3. Nieuwlaat R,
    4. de Vos CB,
    5. Crijns HJ,
    6. Lip GY

    (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093–1100.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Ahrens I,
    2. Lip GY,
    3. Peter K

    (2010) New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 104:49–60.

    OpenUrlPubMedWeb of Science
13. ↵
    1. Contractor T,
    2. Levin V,
    3. Martinez MW,
    4. Marchlinski FE

    (2013) Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era. Postgrad Med 125:34–44.

    OpenUrlCrossRef
14. ↵
    1. U.S. Food and Drug Administration

    FDA approves Pradaxa to prevent stroke in people with atrial fibrillation, Available from:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. Updated 2013 April 19, Accessed 2014 November.
15. ↵
    1. Marshall S,
    2. Fearon P,
    3. Dawson J,
    4. Quinn TJ

    (2013) Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res 13:29–42.

    OpenUrl
16. ↵
    1. Connolly SJ,
    2. Ezekowitz MD,
    3. Yusuf S,
    4. Eikelboom J,
    5. Oldgren J,
    6. Parekh A,
    7. et al.

    (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151.

    OpenUrlCrossRefPubMedWeb of Science
17. 1. Wallentin L,
    2. Yusuf S,
    3. Ezekowitz MD,
    4. Alings M,
    5. Flather M,
    6. Franzosi MG,
    7. et al.

    (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376:975–983.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    1. Eikelboom JW,
    2. Wallentin L,
    3. Connolly SJ,
    4. Ezekowitz M,
    5. Healey JS,
    6. Oldgren J,
    7. et al.

    (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123:2363–2372.

    OpenUrlAbstract/FREE Full Text
19. ↵
    1. Southworth MR,
    2. Reichman ME,
    3. Unger EF

    (2013) Dabigatran and postmarketing reports of bleeding. N Engl J Med 368:1272–1274.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    1. Hernandez I,
    2. Baik SH,
    3. Piñera A,
    4. Zhang Y

    (2015) Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 175:18–24.

    OpenUrl
21. ↵
    1. Joppi R,
    2. Cinconze E,
    3. Mezzalira L,
    4. Pase D,
    5. Poggiani C,
    6. Rossi E,
    7. et al.

    (2013) Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study. Eur J Intern Med 24:318–323.

    OpenUrlCrossRefPubMed
22. ↵
    1. Camm AJ,
    2. Lip GY,
    3. De Caterina R,
    4. Savelieva I,
    5. Atar D,
    6. Hohnloser SH,
    7. et al.

    (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747.

    OpenUrlCrossRefPubMedWeb of Science
23. 1. You JJ,
    2. Singer DE,
    3. Howard PA,
    4. Lane DA,
    5. Eckman MH,
    6. Fang MC,
    7. et al.

    (2012) Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e531S–e575S.

    OpenUrlCrossRefPubMedWeb of Science
24. ↵
    1. Skanes AC,
    2. Healey JS,
    3. Cairns JA,
    4. Dorian P,
    5. Gillis AM,
    6. McMurtry MS,
    7. et al.

    (2012) Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 28:125–136.

    OpenUrlCrossRefPubMed
25. ↵
    1. Lakkireddy D,
    2. Reddy YM,
    3. Di Biase L,
    4. Vanga SR,
    5. Santangeli P,
    6. Swarup V,
    7. et al.

    (2012) Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 59:1168–1174.

    OpenUrlFREE Full Text
26. ↵
    1. Connolly SJ,
    2. Reilly PA,
    3. Pogue J,
    4. Eikelboom J,
    5. Oldgren J,
    6. Ezekowitz MD,
    7. et al.

    (2012) Randomized comparison of the effects of two doses of dabigatran etexilate on clinical outcomes over 4.3 years: results of the RELY-ABLE double-blind randomized trial. Circulation 126:2793.

    OpenUrl
27. ↵
    1. Connolly SJ,
    2. Ezekowitz MD,
    3. Yusuf S,
    4. Reilly PA,
    5. Wallentin L

    (2010) Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med 363:1875–1876.

    OpenUrlCrossRefPubMedWeb of Science
28. ↵
    1. Lip GY,
    2. Larsen TB,
    3. Skjøth F,
    4. Rasmussen LH

    (2012) Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 60:738–746.

    OpenUrlFREE Full Text
29. ↵
    1. Uchino K,
    2. Hernandez AV

    (2012) Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 172:397–402.

    OpenUrlCrossRefPubMedWeb of Science
30. ↵
    1. Larsen TB,
    2. Rasmussen LH,
    3. Skjøth F,
    4. Due KM,
    5. Callréus T,
    6. Rosenzweig M,
    7. et al.

    (2013) Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 61:2264–2273.

    OpenUrlFREE Full Text
31. ↵
    1. Huisman MV,
    2. Lip GY,
    3. Diener HC,
    4. Dubner SJ,
    5. Halperin JL,
    6. Ma CS,
    7. et al.

    (2014) Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J 167:329–334.

    OpenUrlCrossRefPubMedWeb of Science
32. ↵
    1. Dogliotti A,
    2. Paolasso E,
    3. Giugliano RP

    (2013) Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin. Clin Cardiol 36:61–67.

    OpenUrlCrossRefPubMed
33. ↵
    1. Granger CB,
    2. Alexander JH,
    3. McMurray JJ,
    4. Lopes RD,
    5. Hylek EM,
    6. Hanna M,
    7. et al.

    (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992.

    OpenUrlCrossRefPubMedWeb of Science
34. 1. Giugliano RP,
    2. Ruff CT,
    3. Braunwald E,
    4. Murphy SA,
    5. Wiviott SD,
    6. Halperin JL,
    7. et al.

    (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104.

    OpenUrlCrossRefPubMedWeb of Science
35. ↵
    1. Patel MR,
    2. Mahaffey KW,
    3. Garg J,
    4. Pan G,
    5. Singer DE,
    6. Hacke W,
    7. et al.

    (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891.

    OpenUrlCrossRefPubMedWeb of Science
36. ↵
    1. Larock AS,
    2. Mullier F,
    3. Sennesael AL,
    4. Douxfils J,
    5. Devalet B,
    6. Chatelain C,
    7. et al.

    (2014) Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. Ann Pharmacother 48:1258–1268.

    OpenUrlCrossRefPubMed
37. ↵
    1. Troncoso A,
    2. Diogène E

    (2014) Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs. Euro J Clin Pharmacol 70:249–250.

    OpenUrl
38. ↵
    1. Malmström RE,
    2. Godman BB,
    3. Diogene E,
    4. Baumgärtel C,
    5. Bennie M,
    6. Bishop I,
    7. et al.

    (2013) Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol 4:39.

    OpenUrl
39. ↵
    1. Harper P,
    2. Young L,
    3. Merriman E

    (2012) Bleeding Risk with Dabigatran in the Frail Elderly. N Eng J Med 366:864–866.

    OpenUrlCrossRefPubMed
40. ↵
    1. Reilly PA,
    2. Lehr T,
    3. Haertter S,
    4. Connolly SJ,
    5. Yusuf S,
    6. Eikelboom JW,
    7. et al.

    (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 63:321–328.

    OpenUrlFREE Full Text
41. ↵
    1. Cohen D

    (2014) Dabigatran: how the drug company withheld important analyses. BMJ 349:g4670.

    OpenUrlFREE Full Text
42. ↵
    1. Moore TJ,
    2. Cohen MR,
    3. Mattison DR

    (2014) Dabigatran, bleeding, and the regulators. BMJ 349:g4517.

    OpenUrlFREE Full Text
43. ↵
    1. Huisman MV,
    2. Lip GY,
    3. Diener HC,
    4. Brueckmann M,
    5. van Ryn J,
    6. Clemens A

    (2012) Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 107:838–847.

    OpenUrlCrossRefPubMed
44. ↵
    1. Godman B,
    2. Malmström RE,
    3. Diogene E,
    4. Jayathissa S,
    5. McTaggart S,
    6. Cars T,
    7. et al.

    (2014) Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front Pharmacol 5:109.

    OpenUrl